Breast Cancer Coverage from Every Angle

Shom Goel, MD, PhD, on Use of CDK4/6 Inhibitors in Breast Cancer to Enhance Antitumor Immunity

Posted: Thursday, January 10, 2019

Shom Goel, MD, PhD, of the Dana-Farber Cancer Institute, discusses preclinical data that suggest CDK4/6 inhibitors enhance antitumor immunity, a phenomenon that might help improve outcomes for people with advanced disease.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.